Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Recurrence 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Rubinstein-Taybi Syndrome 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 116fludarabine phosphate 101Busulfan 83Tacrolimus 75fludarabine 73Mycophenolic Acid 71Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 59Antilymphocyte Serum 58Cyclosporine 53Azacitidine 53Melphalan 50Cytarabine 47Filgrastim 43Methotrexate 41Granulocyte Colony-Stimulating Factor 34Decitabine 33Radiotherapy 28Thiotepa 27Cord Blood Stem Cell Transplantation 27thymoglobulin 26Stem Cell Transplantation 26Clofarabine 22Methylprednisolone 20Sirolimus 19Alemtuzumab 16venetoclax 15Specimen Handling 14sargramostim 13Etoposide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic Syndromes × mocetinostat × Clear all
NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Mirati Therapeutics Inc.

Phase 2 Terminated
35 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mirati Therapeutics Inc.

Phase 2 Terminated
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡